LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

Kodu・Aktsiate loetelu・Amicus Therapeutics Inc

Amicus Therapeutics Inc

Suletud

SektorTervishoid

14.32 -0.14

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

14.31

Max

14.34

Põhinäitajad
By Trading Economics
Sissetulek	-16M 1.7M
Müük	16M 185M
Kasumimarginaal	0.912
Töötajad	499
EBITDA	-43M 5M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-1.81% downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	30. apr 2026

Turustatistika
By TradingEconomics
Turukapital	16M 4.5B
Eelmine avamishind	14.46
Eelmine sulgemishind	14.32

Uudiste sentiment

By Acuity

10%

90%

36 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

5.925 / 7.38 Toetus ja vastupanu

Amicus Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. dets 2025, 14:38 UTC

Tulu

Kuumad aktsiad

Stocks to Watch Friday: Nike, Oracle, FedEx, Sony -- WSJ

Võrdlus sarnastega

Hinnamuutus

Amicus Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-1.81% langus

12 kuu keskmine prognoos

Keskmine 14.08 USD -1.81%

Kõrge 14.5 USD

Madal 12 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Amicus Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Amicus Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

5.925 / 7.38Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

36 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.